CytoSorbents Corporation (OTCBB: CTSO) is a critical care-focused therapeutic device company using blood purification to treat life-threatening illnesses. Its purification technology is based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and absorption.
The company has announced that it will be exhibiting at the 2012 Symposium of Intensive Medicine and Intensive Care from February 22-24, 2012 in Bremen, Germany. CytoSorbents "will be available to discuss its CytoSorb(TM) technology in Booth # A7 in the Bremen Exhibition and Conference Centre. This conference attracts an estimated 4,000 participants and is the largest independent German association event to focus on critical care and intensive care medicine."
Chief Executive Officer Dr. Phillip Chan commented,
"We are pleased to participate in this conference that assembles key German thought leaders and physicians in critical care medicine. We continue to increase the market visibility and availability of our CytoSorb(TM) extracorporeal cytokine filter ahead of our broader market launch in Germany planned for this spring. There continues to be strong physician interest in the ability to reduce cytokine storm in a variety of serious conditions, including sepsis, burn injury, trauma, lung injury and pancreatitis. This interest has extended into a number of new additional applications where cytokines are elevated, which we will detail in the future as they continue to develop. We remain very excited about the new critical care treatment options that CytoSorb(TM) may provide."